These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 16148437)

  • 21. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.
    Vemuri VK; Janero DR; Makriyannis A
    Physiol Behav; 2008 Mar; 93(4-5):671-86. PubMed ID: 18155257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The psychiatric side-effects of rimonabant.
    Moreira FA; Crippa JA
    Braz J Psychiatry; 2009 Jun; 31(2):145-53. PubMed ID: 19578688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alterations in behavioral flexibility by cannabinoid CB1 receptor agonists and antagonists.
    Hill MN; Froese LM; Morrish AC; Sun JC; Floresco SB
    Psychopharmacology (Berl); 2006 Aug; 187(2):245-59. PubMed ID: 16752140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of the basolateral nucleus of the amygdala in endocannabinoid-mediated stress-induced analgesia.
    Connell K; Bolton N; Olsen D; Piomelli D; Hohmann AG
    Neurosci Lett; 2006 Apr; 397(3):180-4. PubMed ID: 16378681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocannabinoids in the regulation of appetite and body weight.
    Kirkham TC
    Behav Pharmacol; 2005 Sep; 16(5-6):297-313. PubMed ID: 16148436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of endocannabinoids and cannabinoid CB1 receptors in alcohol-related behaviors.
    Hungund BL; Basavarajappa BS
    Ann N Y Acad Sci; 2004 Oct; 1025():515-27. PubMed ID: 15542757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Attenuation of allergic contact dermatitis through the endocannabinoid system.
    Karsak M; Gaffal E; Date R; Wang-Eckhardt L; Rehnelt J; Petrosino S; Starowicz K; Steuder R; Schlicker E; Cravatt B; Mechoulam R; Buettner R; Werner S; Di Marzo V; Tüting T; Zimmer A
    Science; 2007 Jun; 316(5830):1494-7. PubMed ID: 17556587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The great divide: Separation between in vitro and in vivo effects of PSNCBAM-based CB
    Gamage TF; Farquhar CE; Lefever TW; Thomas BF; Nguyen T; Zhang Y; Wiley JL
    Neuropharmacology; 2017 Oct; 125():365-375. PubMed ID: 28803965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebus monkeys.
    Madsen MV; Peacock L; Werge T; Andersen MB
    J Psychopharmacol; 2006 Sep; 20(5):622-8. PubMed ID: 16533866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex.
    Rubino T; Realini N; Castiglioni C; Guidali C; Viganó D; Marras E; Petrosino S; Perletti G; Maccarrone M; Di Marzo V; Parolaro D
    Cereb Cortex; 2008 Jun; 18(6):1292-301. PubMed ID: 17921459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core.
    Schoffelmeer AN; Hogenboom F; Wardeh G; De Vries TJ
    Neuropharmacology; 2006 Sep; 51(4):773-81. PubMed ID: 16806307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors.
    Moreira FA; Kaiser N; Monory K; Lutz B
    Neuropharmacology; 2008 Jan; 54(1):141-50. PubMed ID: 17709120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors.
    Ottani A; Leone S; Sandrini M; Ferrari A; Bertolini A
    Eur J Pharmacol; 2006 Feb; 531(1-3):280-1. PubMed ID: 16438952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involvement of central and peripheral cannabinoid receptors on antinociceptive effect of tetrahydrocannabinol in muscle pain.
    Bagüés A; Martín MI; Sánchez-Robles EM
    Eur J Pharmacol; 2014 Dec; 745():69-75. PubMed ID: 25446925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys.
    Schindler CW; Redhi GH; Vemuri K; Makriyannis A; Le Foll B; Bergman J; Goldberg SR; Justinova Z
    Neuropsychopharmacology; 2016 Aug; 41(9):2283-93. PubMed ID: 26888056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats.
    Calik MW; Carley DW
    Sleep; 2017 Sep; 40(9):. PubMed ID: 28934522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of cannabinoid CB2 receptors in glucose homeostasis in rats.
    Bermudez-Silva FJ; Sanchez-Vera I; Suárez J; Serrano A; Fuentes E; Juan-Pico P; Nadal A; Rodríguez de Fonseca F
    Eur J Pharmacol; 2007 Jun; 565(1-3):207-11. PubMed ID: 17499236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Entopeduncular nucleus endocannabinoid system modulates sleep-waking cycle and mood in rats.
    Méndez-Díaz M; Caynas-Rojas S; Arteaga Santacruz V; Ruiz-Contreras AE; Aguilar-Roblero R; Prospéro-García O
    Pharmacol Biochem Behav; 2013 Jun; 107():29-35. PubMed ID: 23584096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice.
    Shearman LP; Rosko KM; Fleischer R; Wang J; Xu S; Tong XS; Rocha BA
    Behav Pharmacol; 2003 Dec; 14(8):573-82. PubMed ID: 14665974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Behavioral effects of cannabinoid agents in animals.
    Chaperon F; Thiébot MH
    Crit Rev Neurobiol; 1999; 13(3):243-81. PubMed ID: 10803637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.